TC
DNA icon

Titleist Capital’s Ginkgo Bioworks DNA Stock Holding History

Titleist Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$3.9M Buy
57,745
+1,252
+2% +$115K 0.91% 21
2022
Q3 		$7.05M Buy
56,493
+24,101
+74% +$2.87M 1.61% 15
2022
Q2 		$3.08M Buy
32,392
+4,337
+15% +$529K 0.75% 29
2022
Q1 		$4.52M Buy
28,055
+2,409
+9% +$469K 0.9% 28
2021
Q4 		$8.53M Buy
+25,646
New +$12.2M 1.64% 15

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Titleist Capital's DNA Position: Q4 2022 in Review

Titleist Capital increased its Ginkgo Bioworks (DNA) stake by 2.2% in Q4 2022, buying an estimated $115K and bringing the position to 57,745 shares worth $3.9M. The position accounts for 0.91% of the portfolio, ranked #21.

Titleist Capital first reported a position in DNA in Q4 2021 and has held it in 5 quarters since. The position peaked at $8.53M in Q4 2021. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

  • Titleist Capital held 57,745 shares of Ginkgo Bioworks worth $3.9M as of Q4 2022.
  • Titleist Capital bought 1,252 Ginkgo Bioworks shares in Q4 2022, an estimated $115K.
  • Ginkgo Bioworks made up 0.91% of Titleist Capital's portfolio in Q4 2022, its #21 holding.
  • Titleist Capital first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 5 quarters since.
  • Titleist Capital's Ginkgo Bioworks position peaked at $8.53M in Q4 2021.
  • 320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Titleist Capital's 13F filing for Q4 2022, filed 12 Jan 2023.